Study

A biomarker for multiple sclerosis

Patients with multiple sclerosis often receive a "hit and miss" treatment when the disease breaks out. A blood analysis is now for the first time able to reveal which of the two most important first-line drugs is better suited for which patients.

Stefanie Kürten and her colleague Damiano Rovituso.
Stefanie Kürten and her colleague Damiano Rovituso.
Source: JMU/Robert Emmerich
A blood analysis is able to show which therapy is better suited for patients...
A blood analysis is able to show which therapy is better suited for patients with multiple sclerosis.
Source: JMU/Michael Christof

More than two million people worldwide suffer from multiple sclerosis (MS). In this disease, which progresses by successive flare-ups, the immune system destroys "by mistake" cells in the brain and the spinal cord. This leads to spots of inflammation that cause more or less severe symptoms, depending on their location and size: the affected persons may feel a tingling sensation in their arms and legs, they trip frequently or have vision problems. In extreme cases, they can no longer walk on their own and are confined to a wheelchair.

So far, there is no cure for multiple sclerosis, but the available drugs can at least mitigate the symptoms. "We cannot even predict when a patient will have a next flare-up, or whether MS will develop after a first flare-up", says Stefanie Kürten, Professor of Anatomy and Cell Biology at the Julius-Maximilians-Universität Würzburg, JMU.

Although new drugs have been introduced to the market recently, there is no way of telling which of them is best suited for which patients. "Quite often doctors simply try one drug, and if it doesn't work, they try the next", says Dr. Kürten. This is, of course, very frustrating for both patient and doctor – all the more because it is a known fact that MS must be treated efficiently at an early stage to prevent its long-term progress and the loss of brain tissue.

B cells can be used as biomarkers

Dr. Kürten's team has now succeeded for the first time in developing a biomarker for MS: a blood analysis may be able to help decide which of the two "therapy classics" should be used in the early phase of the disease. Patients with autoreactive B cells in their blood would need to be treated with Copaxone, whereas patients without such B cells are likely to benefit more from an IFN-beta therapy.

These findings were made in cooperation with TEVA Pharmaceutical Industries and Cellular Technology Limited.

How is the biomarker test performed? "All we need are blood samples from the patients", explains Dr. Kürten’s colleague Damiano Rovituso. The white blood cells are isolated from the samples and stimulated for four days in a cell culture so that the immune system's memory B cells start producing antibodies. "We then determine whether these antibodies attack the tissue of the central nervous system." This is a highly specific test for multiple sclerosis, because B lymphocytes and their antibodies can contribute directly to nerve fibre damage.

Several hospitals contribute to the study

The findings of the study have been published in the "Scientific Reports" journal. The scientists have performed tests on a total of 57 MS patients. Contributors to the study were the Departments of Neurology of the University Hospitals of Cologne and Würzburg, as well as the Klinikum Augsburg, the Caritas hospital Bad Mergentheim and the Charité Universitätsmedizin Berlin.

Clinical study with more patients needed

Before these new insights may find their way to standard treatment, they have to be confirmed by a clinical study with a larger number of patients. Stefanie Kürten says that such a study is expected to start in 2015, funded by the pharmaceutical company TEVA Pharmaceutical Industries.

The study will be performed in cooperation with Stefan Braune, Professor of Neurology at the Technical University of Munich, TUM. He will recruit for the study patients from all over Germany through the nationwide network NeuroTransData GmbH.

Next step: Explore the effect of antibodies

In a next step, Stefanie Kürten wants to find out which target structures in the brain are attacked by the antibodies from the memory B cells of individual positive tested patients. By this she expects to gain further insight into the course of the disease. "We may then be able to develop therapies that attack the pathogenic B cells directly."


Literature:
„The brain antigen-specific B cell response correlates with glatiramer acetate responsiveness in relapsing-remitting multiple sclerosis patients”, Damiano M. Rovituso, Cathrina E. Duffy, Michael Schroeter, Claudia C. Kaiser, Christoph Kleinschnitz, Antonios Bayas, Rebecca Elsner & Stefanie Kuerten. Scientific Reports 5, Article number 14265 (2015), DOI: 10.1038/srep14265


Source: Julius-Maximilians-Universität Würzburg.

09.12.2015

Read all latest stories

Related articles

Photo

Ophthalmology

Potential predictor of glaucoma damage identified

Glaucoma, a leading cause of blindness worldwide, most often is diagnosed during a routine eye exam. Over time, elevated pressure inside the eye damages the optic nerve, leading to vision loss.…

Photo

Assessment of brain tumour treatment response

Developing AI algorithms for earlier glioblastoma detection

Novel advanced imaging biomarkers are being developed in a series of studies at several UK centres that may lead to the earlier assessment of treatment response to glioblastoma (GBM) and a better…

Photo

Dementia diagnostics

Lack of sleep might throw off Alzheimer’s test

A preliminary study has found that when young, healthy men were deprived of just one night of sleep, they had higher levels of tau, a biomarker for Alzheimer’s disease, in their blood than when…

Related products

Sarstedt – Cell Culture Products

Specialties

Sarstedt – Cell Culture Products

SARSTEDT AG & CO. KG